Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298973 · ClinicalTrials.gov registry record · Phase 4
Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions
A Phase 4 study of Cataracts, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT01298973: Completed Phase 4 study of Cataracts, sponsored by Innovative Medical.
NCT01298973 is a Phase 4 study of Cataracts that has completed, run by Innovative Medical. The registered enrollment target is 50 participants, below the 92-participant average among 8 other Cataracts trials with a reported enrollment target (46% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01298973, a Phase 4 study of Cataracts, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Viscoat
Study Locations (2)
Florida
- Florida Eye Microsurgical Institute - Boynton Beach
- Eye Physicians of Central Florida - Maitland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 4 |
What the finished NCT01298973 record still lists
NCT01298973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 92-participant average among 8 other Cataracts trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Cataracts appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT01298973 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01298973 about?
NCT01298973 is a clinical study titled "Dispervise Ophthalmic Viscoelastic as an Agent to Ensure Watertight Wound Closure After Clear Corneal Cataract Incisions". The purpose of this study is to look at the ability of Viscoat to ensure proper wound closure.
What is the current status of trial NCT01298973?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2011-01. Estimated completion is 2012-01.
What conditions does trial NCT01298973 study?
This clinical trial studies the following conditions: Cataracts.
What interventions are being tested in trial NCT01298973?
The interventions under investigation include: Saline (DRUG), Viscoat (DRUG).
Who is sponsoring clinical trial NCT01298973?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01298973 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataracts
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01298973's enrollment target sits among peer trials
50 6th of 8 higher than 3 of 8 other Cataracts trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataracts trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
COMPLETED · Phase 4
-
Clear Corneal Incisions and Arcuate Incisions Utilizing FemtoSecond Laser Technology for Cataract Surgery
COMPLETED · Phase 4
-
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
COMPLETED · Phase 4
-
Randomized Comparison of the Abbott WHITESTAR Signature System With Ellips Tranversal Ultrasound vs. the Alcon Infiniti With the Ozil Torsional Handpiece in Phacoemulsification: A Contralaterally-Controlled Trial
COMPLETED · Phase 4
-
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia